Re: Effort To Launch Breast Cancer Treatment Shows Complexities Of Drug Development
IMO this article doesn't do a good job of addressing actual issue at hand. It talks about FDA's role of ensuring that drug is safe, but in T-DM1's case FDA for some absurd and surely with respect to targeted medicine outdated reason refused to even consider looking at the data. That decision send this program in a two-plus year tailspin.
|